Edition:
United States

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

86.27USD
18 Jan 2019
Change (% chg)

$-0.32 (-0.37%)
Prev Close
$86.59
Open
$86.99
Day's High
$86.99
Day's Low
$85.87
Volume
3,970,311
Avg. Vol
2,574,128
52-wk High
$106.67
52-wk Low
$58.61

Select another date:

Fri, Jan 4 2019

Photo

Celgene, Bristol-Myers set $2.2 billion termination fee for their mega deal

Celgene Corp and Bristol-Myers Squibb Co will have to pay $2.2 billion if either of the drugmakers walks away from their $74 billion merger announced on Thursday, according to a regulatory filing.

Celgene, Bristol-Myers set $2.2 bln termination fee for their mega deal

Jan 4 Celgene Corp and Bristol-Myers Squibb Co will have to pay $2.2 billion if either of the drugmakers walks away from their $74 billion merger announced on Thursday, according to a regulatory filing.

BRIEF-Ribon Therapeutics Raises $65 Mln

* RIBON THERAPEUTICS - RAISED $65 MILLION IN FINANCING LED BY NOVARTIS VENTURE FUND, WITH JOHNSON & JOHNSON INNOVATION - JJDC, CELGENE, EXISTING INVESTORS

Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal

Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion, combining two of the world's largest cancer drug businesses in the biggest pharmaceutical deal ever. | Video

UPDATE 7-Bristol-Myers to buy Celgene for $74 bln in largest biopharma deal

Jan 3 Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion, combining two of the world's largest cancer drug businesses in the biggest pharmaceutical deal ever.

Grant & Eisenhofer settles fee fight with Celgene whistleblower

The law firm Grant & Eisenhofer has agreed to settle a lawsuit it filed in 2017 in a bid to obtain a cut of the $78 million that a former whistleblower client was awarded for her role in securing a $280 million settlement with drugmaker Celgene Corp.

Father and son advised on opposite sides of Bristol-Celgene deal

For most U.S. families, the holidays are all about gathering around the fireplace, overeating at festive dinners, and playing the occasional board game. But this year, a father and son were also working on the biggest pharmaceutical acquisition of all time.

Father and son advised on opposite sides of Bristol-Celgene deal

Jan 3 For most U.S. families, the holidays are all about gathering around the fireplace, overeating at festive dinners, and playing the occasional board game. But this year, a father and son were also working on the biggest pharmaceutical acquisition of all time.

Cost to insure Bristol-Myers debt jumps as leverage balloons

NEW YORK The cost to insure Bristol-Myers Squibb debt hit its highest point since May 2010 on Thursday, following the announcement that the U.S. pharmaceutical company would acquire rival Celgene Corp in a deal worth about $74 billion.

UPDATE 1-Cost to insure Bristol-Myers debt jumps as leverage balloons

NEW YORK, Jan 3 The cost to insure Bristol-Myers Squibb debt hit its highest point since May 2010 on Thursday, following the announcement that the U.S. pharmaceutical company would acquire rival Celgene Corp in a deal worth about $74 billion.

Select another date: